118 related articles for article (PubMed ID: 6609176)
1. Second malignancies in cutaneous T cell lymphoma.
Olsen EA; Delzell E; Jegasothy BV
J Am Acad Dermatol; 1984 Feb; 10(2 Pt 1):197-204. PubMed ID: 6609176
[TBL] [Abstract][Full Text] [Related]
2. Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype.
Amber KT; Bloom R; Nouri K
Am J Clin Dermatol; 2016 Feb; 17(1):71-7. PubMed ID: 26386881
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous T-cell lymphoma is associated with increased risk of lymphoma, melanoma, lung cancer, and bladder cancer.
Goyal A; O'Leary D; Goyal K; Patel K; Pearson D; Janakiram M
J Am Acad Dermatol; 2021 Dec; 85(6):1418-1428. PubMed ID: 32822803
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
Ghazawi FM; Netchiporouk E; Rahme E; Tsang M; Moreau L; Glassman S; Provost N; Gilbert M; Jean SE; Pehr K; Sasseville D; Litvinov IV
Cancer; 2017 Sep; 123(18):3550-3567. PubMed ID: 28493286
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis.
Goyal A; O'Leary D; Goyal K; Rubin N; Bohjanen K; Hordinsky M; Chen ST; Pongas G; Duncan LM; Lazaryan A
J Am Acad Dermatol; 2020 Aug; 83(2):404-411. PubMed ID: 31374302
[TBL] [Abstract][Full Text] [Related]
6. Risk of second malignancy after cutaneous T-cell lymphoma.
Kantor AF; Curtis RE; Vonderheid EC; van Scott EJ; Fraumeni JF
Cancer; 1989 Apr; 63(8):1612-5. PubMed ID: 2924268
[TBL] [Abstract][Full Text] [Related]
7. Mycosis fungoides associated with B-cell malignancies.
Barzilai A; Trau H; David M; Feinmesser M; Bergman R; Shpiro D; Schiby G; Rosenblatt K; Or R; Hodak E
Br J Dermatol; 2006 Aug; 155(2):379-86. PubMed ID: 16882178
[TBL] [Abstract][Full Text] [Related]
8. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries.
Litvinov IV; Tetzlaff MT; Rahme E; Habel Y; Risser DR; Gangar P; Jennings MA; Pehr K; Prieto VG; Sasseville D; Duvic M
Cancer; 2015 Jun; 121(12):1993-2003. PubMed ID: 25728286
[TBL] [Abstract][Full Text] [Related]
9. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants.
Edelson RL
J Am Acad Dermatol; 1980 Feb; 2(2):89-106. PubMed ID: 6988470
[TBL] [Abstract][Full Text] [Related]
11. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic.
Herro E; Dicaudo DJ; Davis MD; Weaver AL; Swanson DL
J Am Acad Dermatol; 2009 Aug; 61(2):271-5. PubMed ID: 19481294
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia: clinical characteristics, temporal relationships, and survival data in a series of 14 patients at Mayo Clinic.
Chang MB; Weaver AL; Brewer JD
Int J Dermatol; 2014 Aug; 53(8):966-70. PubMed ID: 24134412
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous lymphoma in Argentina: a report of a nationwide study of 416 patients.
Abeldaño A; Enz P; Maskin M; Cervini AB; Torres N; Acosta AC; Narbaitz M; Vanzulli S; Orentrajch M; Villareal MA; Garcia Pazos ML; Arias M; Zambrano Franco EA; Fontana MI; Chuit R
Int J Dermatol; 2019 Apr; 58(4):449-455. PubMed ID: 30294921
[TBL] [Abstract][Full Text] [Related]
14. Coexistent cutaneous T-cell lymphoma and B-cell malignancy. French Study Group on Cutaneous Lymphomas.
Grange F; Avril MF; Esteve E; Joly P; Bosq J; de Murets A; Thomine E; Ortoli JC; Duvillard P; Vaillant L
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):724-31. PubMed ID: 7929916
[TBL] [Abstract][Full Text] [Related]
15. Incidence of primary cutaneous T-cell lymphoma in Norway.
Saunes M; Nilsen TI; Johannesen TB
Br J Dermatol; 2009 Feb; 160(2):376-9. PubMed ID: 18808419
[TBL] [Abstract][Full Text] [Related]
16. Morbidity and Causes of Death in Patients with Cutaneous T-cell Lymphoma in Finland.
Väkevä L; Lipsanen T; Sintonen H; Ranki A
Acta Derm Venereol; 2017 Jun; 97(6):735-738. PubMed ID: 28175924
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma.
Su IJ; Tsai TF; Cheng AL; Chen CC
J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):685-92. PubMed ID: 8227539
[TBL] [Abstract][Full Text] [Related]
18. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.
Criscione VD; Weinstock MA
Arch Dermatol; 2007 Jul; 143(7):854-9. PubMed ID: 17638728
[TBL] [Abstract][Full Text] [Related]
19. The spectrum of cutaneous lymphomas in Japan: a study of 62 cases based on the World Health Organization Classification.
Yasukawa K; Kato N; Kodama K; Hamasaka A; Hata H
J Cutan Pathol; 2006 Jul; 33(7):487-91. PubMed ID: 16872471
[TBL] [Abstract][Full Text] [Related]
20. Mycosis fungoides and Sézary syndrome in Japan. Clinicopathologic study of 107 autopsy cases.
Arai E; Katayama I; Ishihara K
Pathol Res Pract; 1991 May; 187(4):451-7. PubMed ID: 1876527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
